The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry.
ACCELERATE
disease course
idiopathic multicentric Castleman disease
mortality
registry
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
11
04
2022
received:
23
12
2021
accepted:
12
04
2022
pubmed:
5
5
2022
medline:
19
7
2022
entrez:
4
5
2022
Statut:
ppublish
Résumé
Castleman disease (CD) describes a group of rare, potentially fatal lymphoproliferative disorders. To determine factors associated with mortality in CD, we analysed data from deceased patients in the ACCELERATE registry and compared them with matched controls. We analysed demographic, treatment and laboratory data from all deceased CD patients, matched controls and a subgroup of idiopathic multicentric Castleman disease (iMCD) patients. Of the 140 patients in ACCELERATE with a confirmed CD diagnosis, 10 had died. There were 72 patients with confirmed iMCD; six were deceased. The deceased CD cohort had more hospitalisations per year, higher overall hospitalisations and more days hospitalised per month, and received more treatment regimens per year than the matched-control group. Analysis of laboratory values showed a significantly decreased absolute lymphocyte count at months 3 and 6 in the deceased cohort compared with controls. Among iMCD patients, there was a higher proportion of iMCD-TAFRO (thrombocytopenia, anasarca, fever, reticulin myelofibrosis, renal dysfunction and organomegaly) cases in the deceased group. The deceased iMCD group had significantly lower immunoglobulin M, international normalised ratio and platelet count. These data demonstrate that there may be differences between patients who have fatal and non-fatal outcomes, and provide preliminary suggestions for parameters to evaluate further.
Identifiants
pubmed: 35507638
doi: 10.1111/bjh.18214
pmc: PMC9544190
mid: NIHMS1828669
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
307-316Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL141408
Pays : United States
Informations de copyright
© 2022 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Am J Hematol. 2021 Oct 1;96(10):1241-1252
pubmed: 34265103
Blood. 2014 May 8;123(19):2924-33
pubmed: 24622327
Blood. 2017 Mar 23;129(12):1646-1657
pubmed: 28087540
Br J Haematol. 2022 Jul;198(2):307-316
pubmed: 35507638
Front Med (Lausanne). 2017 Sep 22;4:149
pubmed: 29018798
J Blood Med. 2018 Jan 22;9:15-23
pubmed: 29403325
Am J Hematol. 2016 Feb;91(2):220-6
pubmed: 26805758
Blood. 2020 Apr 16;135(16):1353-1364
pubmed: 32106302
Blood Adv. 2020 Dec 8;4(23):6039-6050
pubmed: 33284946
PLoS One. 2019 Jun 26;14(6):e0218660
pubmed: 31242229
Chin Med J (Engl). 2018 Aug 5;131(15):1868-1870
pubmed: 30058586
Blood. 2000 Feb 15;95(4):1406-12
pubmed: 10666218
JCI Insight. 2020 May 7;5(9):
pubmed: 32376796
Med Oncol. 2013 Mar;30(1):492
pubmed: 23400962
N Engl J Med. 2020 Dec 3;383(23):2255-2273
pubmed: 33264547
PLoS Med. 2018 Nov 1;15(11):e1002685
pubmed: 30383787
Br J Haematol. 2019 Jan;184(2):232-241
pubmed: 30203839
Cancer. 1972 Mar;29(3):670-83
pubmed: 4551306
Am J Hematol. 2020 Dec;95(12):1553-1561
pubmed: 32894785
Br J Haematol. 2012 Aug;158(3):421-3
pubmed: 22583139
Int J Lab Hematol. 2020 Dec;42(6):761-765
pubmed: 32779838
Cell Rep Med. 2020 Dec 22;1(9):100158
pubmed: 33377129
Am J Hematol. 2012 Nov;87(11):997-1002
pubmed: 22791417
Blood. 2018 Nov 29;132(22):2323-2330
pubmed: 30487129
Am J Hematol. 2019 Sep;94(9):975-983
pubmed: 31222819
Blood Adv. 2021 Sep 14;5(17):3445-3456
pubmed: 34438448
Clin Cancer Res. 2015 Mar 1;21(5):950-4
pubmed: 25601959
Br J Haematol. 2015 Jun;169(6):834-42
pubmed: 25824806
Hematol Oncol Clin North Am. 2018 Feb;32(1):65-73
pubmed: 29157620
J Clin Invest. 2019 Aug 13;129(10):4451-4463
pubmed: 31408438
Medicine (Baltimore). 2021 Jul 16;100(28):e26503
pubmed: 34260527
Blood Res. 2014 Dec;49(4):253-8
pubmed: 25548759
Blood. 2020 May 7;135(19):1673-1684
pubmed: 32206779
Am J Hematol. 2018 Jul;93(7):902-912
pubmed: 29675946
Blood. 2018 Nov 15;132(20):2115-2124
pubmed: 30181172
Mod Rheumatol. 2018 Jan;28(1):161-167
pubmed: 28880697
Lancet Oncol. 2014 Aug;15(9):966-74
pubmed: 25042199
Cancer Sci. 2018 Jan;109(1):199-206
pubmed: 29124835
Mod Rheumatol. 2019 Mar;29(2):302-305
pubmed: 30285516
Am J Hematol. 2006 Apr;81(4):303-4
pubmed: 16550518
Oncogene. 2020 Apr;39(15):3218-3225
pubmed: 32051554
Br J Haematol. 2018 Jan;180(2):206-216
pubmed: 29143319
Ter Arkh. 2015;87(7):64-71
pubmed: 26390727